Life Science Intermediates Market Consolidation: Who will not survive?

Life Science Intermediates Market Consolidation: Who will not survive?

Category : Materials & Chemicals
January  2014 


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?
- How will the current trends affect the major market segments?
- Which companies will enter the market and which will not survive? This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies. The report presents:

  • Internally developed and acquired technologies, and related capabilities.
  • Proprietary technologies and patent litigations.

The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 35 pages

image
Can't read the image ? refresh here.


Enquiry Before Buy
image
Can´t read the image ? refresh here.